Daniel B Hawcutt1, Pramod Mainie, Andrew Riordan, Rosalind L Smyth, Munir Pirmohamed. 1. Division of Developmental and Reproductive Medicine, University of Liverpool, Liverpool Northwick Park Hospital, Watford Road, Harrow, London Alder Hey Children's Hospital, Liverpool Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Abstract
AIMS: The UK Medicines and Healthcare products Regulatory Agency (MHRA) runs a national spontaneous reporting system (Yellow Card Scheme) to collect 'suspected' adverse drug reaction (ADR) data. MHRA advice is to report all suspected ADRs in paediatric (<17 years) patients. METHODS: Data on all ADRs reported to the MHRA in patients <17 years from the years 2000-9 were supplied in two datasets, inclusive and exclusive of vaccines. RESULTS: Of 222 755 ADR reports received by the MHRA from 2000-9, 31726 (14.2%) were in children <17 years. The number of reports in 2000 was greater than in subsequent years (12035) due to a national vaccination programme (Meningococcal Serogroup C conjugate vaccine). The median number of ADR reports per annum (2001-2009) for children was 2146 (95% CI 1801, 2575). Vaccines were included in 22102 (66.5%) paediatric ADR reports, with Meningococcal Serogroup C conjugate vaccine reported most frequently (12106 reports) and headache the commonest symptom (3163). Excluding vaccines, methylphenidate (653 reports) and atomoxetine (491) were the most commonly reported medications, and the most commonly reported symptom was vomiting (374). Reporting by nurses increased from 396 in 2001 to 1295 in 2009 (41.8% of all reports); reporting by doctors stayed constant. Reports from patients, parents or carers more than doubled but remained infrequent (1.5% in 2005, 4.0% in 2009). CONCLUSIONS: Although under-reporting is probably common, the Yellow Card Scheme in the UK receives more than 2000 reports per year on patients <17 years. Nurses now report more suspected ADRs in children than any other healthcare professional.
AIMS: The UK Medicines and Healthcare products Regulatory Agency (MHRA) runs a national spontaneous reporting system (Yellow Card Scheme) to collect 'suspected' adverse drug reaction (ADR) data. MHRA advice is to report all suspected ADRs in paediatric (<17 years) patients. METHODS: Data on all ADRs reported to the MHRA in patients <17 years from the years 2000-9 were supplied in two datasets, inclusive and exclusive of vaccines. RESULTS: Of 222 755 ADR reports received by the MHRA from 2000-9, 31726 (14.2%) were in children <17 years. The number of reports in 2000 was greater than in subsequent years (12035) due to a national vaccination programme (Meningococcal Serogroup C conjugate vaccine). The median number of ADR reports per annum (2001-2009) for children was 2146 (95% CI 1801, 2575). Vaccines were included in 22102 (66.5%) paediatric ADR reports, with Meningococcal Serogroup C conjugate vaccine reported most frequently (12106 reports) and headache the commonest symptom (3163). Excluding vaccines, methylphenidate (653 reports) and atomoxetine (491) were the most commonly reported medications, and the most commonly reported symptom was vomiting (374). Reporting by nurses increased from 396 in 2001 to 1295 in 2009 (41.8% of all reports); reporting by doctors stayed constant. Reports from patients, parents or carers more than doubled but remained infrequent (1.5% in 2005, 4.0% in 2009). CONCLUSIONS: Although under-reporting is probably common, the Yellow Card Scheme in the UK receives more than 2000 reports per year on patients <17 years. Nurses now report more suspected ADRs in children than any other healthcare professional.
Authors: Linda E Silvers; Frederick E Varricchio; Susan S Ellenberg; Carol L Krueger; Robert P Wise; Marcel E Salive Journal: Am J Prev Med Date: 2002-04 Impact factor: 5.043
Authors: David J McLernon; Christine M Bond; Philip C Hannaford; Margaret C Watson; Amanda J Lee; Lorna Hazell; Anthony Avery Journal: Drug Saf Date: 2010-09-01 Impact factor: 5.606
Authors: Daniel B Hawcutt; Nicki-Jayne Russell; Hannah Maqsood; Koushan Kouranloo; Simon Gomberg; Catriona Waitt; Andrew Sharp; Andrew Riordan; Mark A Turner Journal: Br J Clin Pharmacol Date: 2016-09-12 Impact factor: 4.335
Authors: L Lindell-Osuagwu; K Sepponen; S Farooqui; H Kokki; K Hämeen-Anttila; K Vainio Journal: Eur J Clin Pharmacol Date: 2012-10-24 Impact factor: 2.953
Authors: Kimberly G Blumenthal; Anna R Wolfson; Yu Li; Claire M Seguin; Neelam A Phadke; Aleena Banerji; Elizabeth Mort Journal: J Patient Saf Date: 2021-12-01 Impact factor: 2.844